The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia

The effect on lower urinary tract symptoms and nocturia

Jae Young Joung, Jong Kwan Park, Choal Hee Park, Jung Gu Lee, Byungha Chung, Sung Joon Hong, Choung Soo Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Nocturia is considered to be the main cause of disturbance of sleep maintenance and the quality of life for elderly men. We assessed the effectiveness of administering alpha 1 (A)-adrenoceptor antagonist tamsulosin for the patients with benign prostatic hyperplasia (BPH), and we measured the degree of improvement of the lower urinary tract symptoms and nocturia after treatment. Materials and Methods: From May 2003 to October 2003, 268 patients with BPH were prospectively selected for this study. The patients were treated with tamsulosin at a dose of 0.2mg/day. The effectiveness of tamsulosin was assessed by analyzing the three day voiding diaries and the other parameters, including the International Prostatic Symptom Score (I-PSS), the Bother score, the maximal urinary flow rate (Qmax), and the postvoid residual urine. The data for these parameters were acquired at baseline and after 4 and 12 weeks of treatment. We investigated the differences in the improvement of noctuia in the BPH patients according to the type of nocturia. Results: Of the 268 patients, 189 patients (70.5%) completed the study. The clinical parameters, including the I-PSS, the Bother score, the Qmax and the residual urine showed significant improvement from the baseline. The change of nocturnal frequency was 2.2 at baseline to 1.4 after 12 weeks of treatment. For the subgroups according to the type of nocturia, both the BPH only group and the nocturnal polyuria group showed improvement in the nocturnal frequency and the nocturnal urine volume. Conclusions: Alpha 1 (A) adrenoceptor antagonist, tamsulosin, significantly improved the nocturia as well as the lower urinary tract symptoms, which was confirmed by measuring the clinical parameters. To identify the role of tamsulosin for improving nocturia for patients with BPH, we need to prospective clinical studies according to the type of nocturia.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalKorean Journal of Urology
Volume47
Issue number1
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

tamsulosin
Nocturia
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Adrenergic Receptors
Urine
Therapeutics
Polyuria
Sleep

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{7e8734a9142d4ea8b1edc432d0382ea0,
title = "The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia: The effect on lower urinary tract symptoms and nocturia",
abstract = "Purpose: Nocturia is considered to be the main cause of disturbance of sleep maintenance and the quality of life for elderly men. We assessed the effectiveness of administering alpha 1 (A)-adrenoceptor antagonist tamsulosin for the patients with benign prostatic hyperplasia (BPH), and we measured the degree of improvement of the lower urinary tract symptoms and nocturia after treatment. Materials and Methods: From May 2003 to October 2003, 268 patients with BPH were prospectively selected for this study. The patients were treated with tamsulosin at a dose of 0.2mg/day. The effectiveness of tamsulosin was assessed by analyzing the three day voiding diaries and the other parameters, including the International Prostatic Symptom Score (I-PSS), the Bother score, the maximal urinary flow rate (Qmax), and the postvoid residual urine. The data for these parameters were acquired at baseline and after 4 and 12 weeks of treatment. We investigated the differences in the improvement of noctuia in the BPH patients according to the type of nocturia. Results: Of the 268 patients, 189 patients (70.5{\%}) completed the study. The clinical parameters, including the I-PSS, the Bother score, the Qmax and the residual urine showed significant improvement from the baseline. The change of nocturnal frequency was 2.2 at baseline to 1.4 after 12 weeks of treatment. For the subgroups according to the type of nocturia, both the BPH only group and the nocturnal polyuria group showed improvement in the nocturnal frequency and the nocturnal urine volume. Conclusions: Alpha 1 (A) adrenoceptor antagonist, tamsulosin, significantly improved the nocturia as well as the lower urinary tract symptoms, which was confirmed by measuring the clinical parameters. To identify the role of tamsulosin for improving nocturia for patients with BPH, we need to prospective clinical studies according to the type of nocturia.",
author = "Joung, {Jae Young} and Park, {Jong Kwan} and Park, {Choal Hee} and Lee, {Jung Gu} and Byungha Chung and Hong, {Sung Joon} and Kim, {Choung Soo}",
year = "2006",
month = "1",
day = "1",
doi = "10.4111/kju.2006.47.1.1",
language = "English",
volume = "47",
pages = "1--6",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "1",

}

The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia : The effect on lower urinary tract symptoms and nocturia. / Joung, Jae Young; Park, Jong Kwan; Park, Choal Hee; Lee, Jung Gu; Chung, Byungha; Hong, Sung Joon; Kim, Choung Soo.

In: Korean Journal of Urology, Vol. 47, No. 1, 01.01.2006, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia

T2 - The effect on lower urinary tract symptoms and nocturia

AU - Joung, Jae Young

AU - Park, Jong Kwan

AU - Park, Choal Hee

AU - Lee, Jung Gu

AU - Chung, Byungha

AU - Hong, Sung Joon

AU - Kim, Choung Soo

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Purpose: Nocturia is considered to be the main cause of disturbance of sleep maintenance and the quality of life for elderly men. We assessed the effectiveness of administering alpha 1 (A)-adrenoceptor antagonist tamsulosin for the patients with benign prostatic hyperplasia (BPH), and we measured the degree of improvement of the lower urinary tract symptoms and nocturia after treatment. Materials and Methods: From May 2003 to October 2003, 268 patients with BPH were prospectively selected for this study. The patients were treated with tamsulosin at a dose of 0.2mg/day. The effectiveness of tamsulosin was assessed by analyzing the three day voiding diaries and the other parameters, including the International Prostatic Symptom Score (I-PSS), the Bother score, the maximal urinary flow rate (Qmax), and the postvoid residual urine. The data for these parameters were acquired at baseline and after 4 and 12 weeks of treatment. We investigated the differences in the improvement of noctuia in the BPH patients according to the type of nocturia. Results: Of the 268 patients, 189 patients (70.5%) completed the study. The clinical parameters, including the I-PSS, the Bother score, the Qmax and the residual urine showed significant improvement from the baseline. The change of nocturnal frequency was 2.2 at baseline to 1.4 after 12 weeks of treatment. For the subgroups according to the type of nocturia, both the BPH only group and the nocturnal polyuria group showed improvement in the nocturnal frequency and the nocturnal urine volume. Conclusions: Alpha 1 (A) adrenoceptor antagonist, tamsulosin, significantly improved the nocturia as well as the lower urinary tract symptoms, which was confirmed by measuring the clinical parameters. To identify the role of tamsulosin for improving nocturia for patients with BPH, we need to prospective clinical studies according to the type of nocturia.

AB - Purpose: Nocturia is considered to be the main cause of disturbance of sleep maintenance and the quality of life for elderly men. We assessed the effectiveness of administering alpha 1 (A)-adrenoceptor antagonist tamsulosin for the patients with benign prostatic hyperplasia (BPH), and we measured the degree of improvement of the lower urinary tract symptoms and nocturia after treatment. Materials and Methods: From May 2003 to October 2003, 268 patients with BPH were prospectively selected for this study. The patients were treated with tamsulosin at a dose of 0.2mg/day. The effectiveness of tamsulosin was assessed by analyzing the three day voiding diaries and the other parameters, including the International Prostatic Symptom Score (I-PSS), the Bother score, the maximal urinary flow rate (Qmax), and the postvoid residual urine. The data for these parameters were acquired at baseline and after 4 and 12 weeks of treatment. We investigated the differences in the improvement of noctuia in the BPH patients according to the type of nocturia. Results: Of the 268 patients, 189 patients (70.5%) completed the study. The clinical parameters, including the I-PSS, the Bother score, the Qmax and the residual urine showed significant improvement from the baseline. The change of nocturnal frequency was 2.2 at baseline to 1.4 after 12 weeks of treatment. For the subgroups according to the type of nocturia, both the BPH only group and the nocturnal polyuria group showed improvement in the nocturnal frequency and the nocturnal urine volume. Conclusions: Alpha 1 (A) adrenoceptor antagonist, tamsulosin, significantly improved the nocturia as well as the lower urinary tract symptoms, which was confirmed by measuring the clinical parameters. To identify the role of tamsulosin for improving nocturia for patients with BPH, we need to prospective clinical studies according to the type of nocturia.

UR - http://www.scopus.com/inward/record.url?scp=32444451691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444451691&partnerID=8YFLogxK

U2 - 10.4111/kju.2006.47.1.1

DO - 10.4111/kju.2006.47.1.1

M3 - Article

VL - 47

SP - 1

EP - 6

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 1

ER -